<DOC>
	<DOCNO>NCT00003885</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient recurrent refractory acute leukemia , chronic myeloid leukemia , myelodysplasia , lymphoma , myeloma .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Recurrent Refractory Acute Leukemia , Chronic Myeloide Leukemia , Myelodysplasia , Lymphoma , Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect arsenic trioxide remission rate patient recurrent refractory acute leukemia , blast crisis chronic myeloid leukemia , myelodysplasia , lymphoma , myeloma . II . Determine time progression survival patient treat regimen . III . Determine toxic effect regimen patient . OUTLINE : Patients stratify 1 8 category : first relapse great 6 month complete response v second relapse refractory v prior hematologic disorder v myeloid blast crisis chronic myeloid leukemia v lymphoid leukemia v lymphoma v myeloma v myelodysplasia . Patients receive IV arsenic trioxide 2-3 hour 5 consecutive day 2 day rest . Treatment continue absence disease progression complete response 90 day reach . Upon achieve complete response , treatment discontinue 30 day . Patients exhibit complete response receive second 28 day course consolidation therapy remission start sooner 31 day end induction therapy . Patients follow monthly . PROJECTED ACCRUAL : A total 14-29 patient per lymphoma myeloma stratum total 31 patient per leukemia stratum accrue study within 18-24 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent refractory acute leukemia ( myeloid lymphoid ) , blast crisis chronic myeloid leukemia , myelodysplasia , lymphoma , myeloma FAB subtypes PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 6 week Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL ( except leukemic infiltration dysfunction ) Alkaline phosphatase less 2 time upper limit normal ( except leukemic infiltration dysfunction ) Renal : Creatinine great 2.0 mg/dL Other : No active infection Not pregnant Fertile patient must use effective contraception No history seizure disorder PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 2 week since prior chemotherapy ( except hydroxyurea ) No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent investigational agent Concurrent antibiotic therapy allow stable patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>